AG˹ٷ

STOCK TITAN

[8-K] Aurora Innovation, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Merit Medical Systems (MMSI) � Q2 2025 10-Q highlights

  • Revenue: $382.5 m, up 13.1 % YoY; six-month revenue $737.8 m, up 11.5 %.
  • Mix: Cardiovascular +11 % to $364.0 m; Endoscopy devices +81 % to $18.4 m.
  • Margins: Gross margin 48.3 % (+60 bp); SG&A +19 %, R&D +20 % drove operating margin down 130 bp to 12.3 %.
  • Earnings: Net income $32.6 m (-8.8 %); diluted EPS $0.54 vs $0.61. 1H EPS $1.03 (-5.5 %).
  • Cash flow: 1H operating cash flow $123.9 m (+18 %); capex $34.8 m; acquisitions $122.6 m.
  • Balance sheet: Cash $341.8 m (-9 % YTD); long-term convertible notes $731.8 m; equity $1.49 bn (+7.9 %). Leverage covenants remain compliant.
  • Acquisitions: Closed $126 m Biolife deal in May (hemostatic devices); prior Cook ($210 m) and EGS ($105 m) integrations ongoing. Goodwill now $504.6 m.
  • Tax: Effective rate 24.9 % vs 22.1 %, pressuring earnings.

Overall, strong top-line growth and cash generation were offset by higher operating costs, acquisition spending and a rising tax rate, leading to lower YoY earnings.

Merit Medical Systems (MMSI) � Sintesi 10-Q Q2 2025

  • Ricavi: 382,5 milioni di dollari, +13,1% su base annua; ricavi semestrali 737,8 milioni, +11,5%.
  • Composizione: Cardiovascolare +11% a 364,0 milioni; dispositivi per endoscopia +81% a 18,4 milioni.
  • Margini: Margine lordo al 48,3% (+60 punti base); SG&A +19%, R&S +20% hanno ridotto il margine operativo di 130 punti base al 12,3%.
  • Utile: Utile netto 32,6 milioni (-8,8%); EPS diluito 0,54$ contro 0,61$. EPS 1H 1,03$ (-5,5%).
  • Flusso di cassa: Flusso operativo 1H 123,9 milioni (+18%); investimenti fissi 34,8 milioni; acquisizioni 122,6 milioni.
  • Bilancio: Liquidità 341,8 milioni (-9% da inizio anno); obbligazioni convertibili a lungo termine 731,8 milioni; patrimonio netto 1,49 miliardi (+7,9%). I vincoli di leva finanziaria sono rispettati.
  • Acquisizioni: Concluso accordo Biolife da 126 milioni a maggio (dispositivi emostatici); integrazioni Cook (210 milioni) ed EGS (105 milioni) in corso. Avviamento ora 504,6 milioni.
  • 󾱲à: Aliquota effettiva 24,9% vs 22,1%, che ha pesato sugli utili.

In generale, la forte crescita dei ricavi e la generazione di cassa sono state compensate da costi operativi più elevati, spese per acquisizioni e un aumento dell’aliquota fiscale, portando a un utile inferiore rispetto all’anno precedente.

Merit Medical Systems (MMSI) � Resumen 10-Q Q2 2025

  • Ingresos: 382,5 millones de dólares, un aumento del 13,1% interanual; ingresos semestrales de 737,8 millones, +11,5%.
  • dzDzó: Cardiovascular +11% a 364,0 millones; dispositivos de endoscopía +81% a 18,4 millones.
  • áԱ: Margen bruto del 48,3% (+60 puntos base); SG&A +19%, I+D +20% redujeron el margen operativo en 130 puntos base al 12,3%.
  • Ganancias: Ingreso neto 32,6 millones (-8,8%); EPS diluido 0,54$ vs 0,61$. EPS primer semestre 1,03$ (-5,5%).
  • Flujo de caja: Flujo operativo primer semestre 123,9 millones (+18%); capex 34,8 millones; adquisiciones 122,6 millones.
  • Balance: Efectivo 341,8 millones (-9% en el año); notas convertibles a largo plazo 731,8 millones; patrimonio 1,49 mil millones (+7,9%). Los convenios de apalancamiento se mantienen cumplidos.
  • Adquisiciones: Cerrado acuerdo Biolife por 126 millones en mayo (dispositivos hemostáticos); integraciones previas de Cook (210 millones) y EGS (105 millones) en curso. Plusvalía ahora 504,6 millones.
  • Impuestos: Tasa efectiva 24,9% vs 22,1%, presionando las ganancias.

En general, el fuerte crecimiento de ingresos y generación de efectivo se vieron compensados por mayores costos operativos, gastos en adquisiciones y una tasa impositiva en aumento, lo que llevó a menores ganancias interanuales.

Merit Medical Systems (MMSI) � 2025� 2분기 10-Q 요약

  • 매출: 3� 8,250� 달러, 전년 동기 대� 13.1% 증가; 상반� 매출 7� 3,780� 달러, 11.5% 증가.
  • 구성: 심혈관 부� +11%� 3� 6,400� 달러; 내시� 기기 +81%� 1,840� 달러.
  • 마진: 총이익률 48.3% (+60bp); 판매관리비 19%, 연구개발� 20% 증가� 영업이익률은 130bp 하락� 12.3% 기록.
  • 수익: 순이� 3,260� 달러 (-8.8%); 희석 주당순이� 0.54달러, 전년 0.61달러 대� 하락. 상반� EPS 1.03달러 (-5.5%).
  • ˳금흐름: 상반� 영업현금흐름 1� 2,390� 달러 (+18%); 자본적지� 3,480� 달러; 인수합병 비용 1� 2,260� 달러.
  • 재무: 현금 3� 4,180� 달러 (-9% 연초 대�); 장기 전환사채 7� 3,180� 달러; 자본 14� 9,000� 달러 (+7.9%). 레버리지 조항 준� �.
  • 인수병: 5월에 1� 2,600� 달러 규모� Biolife 인수 완료(지혈기�); 이전 Cook(2� 1,000� 달러) � EGS(1� 500� 달러) 통합 진행 �. 영업� 현재 5� 460� 달러.
  • 세금: 유효세율 24.9% vs 22.1%, 수익� 부담으� 작용.

전반적으� 강한 매출 성장� 현금 창출은 운영 비용 증가, 인수 지�, 세율 상승으로 상쇄되어 전년 대� 수익� 감소했다.

Merit Medical Systems (MMSI) � Points clés du 10-Q T2 2025

  • Chiffre d'affaires : 382,5 M$, en hausse de 13,1 % en glissement annuel ; chiffre d'affaires semestriel de 737,8 M$, en hausse de 11,5 %.
  • Composition : Cardiovasculaire +11 % à 364,0 M$ ; dispositifs d’endoscopie +81 % à 18,4 M$.
  • Marges : Marge brute de 48,3 % (+60 points de base) ; SG&A +19 %, R&D +20 % ont fait baisser la marge opérationnelle de 130 points de base à 12,3 %.
  • Bénéfices : Résultat net 32,6 M$ (-8,8 %) ; BPA dilué 0,54$ contre 0,61$. BPA 1S 1,03$ (-5,5 %).
  • Flux de trésorerie : Flux de trésorerie opérationnel 1S 123,9 M$ (+18 %) ; capex 34,8 M$ ; acquisitions 122,6 M$.
  • Bilan : Trésorerie 341,8 M$ (-9 % depuis le début de l’année) ; obligations convertibles à long terme 731,8 M$ ; capitaux propres 1,49 Md$ (+7,9 %). Les clauses de levier restent respectées.
  • Acquisitions : Clôture de l’accord Biolife à 126 M$ en mai (dispositifs hémostatiques) ; intégrations en cours de Cook (210 M$) et EGS (105 M$). Goodwill désormais à 504,6 M$.
  • Fiscalité : Taux effectif de 24,9 % contre 22,1 %, ce qui pèse sur les bénéfices.

Dans l’ensemble, une forte croissance du chiffre d’affaires et une génération de trésorerie ont été compensées par des coûts opérationnels plus élevés, des dépenses d’acquisition et une hausse du taux d’imposition, entraînant une baisse des bénéfices en glissement annuel.

Merit Medical Systems (MMSI) � Q2 2025 10-Q Highlights

  • Umsatz: 382,5 Mio. USD, +13,1 % im Jahresvergleich; Halbjahresumsatz 737,8 Mio. USD, +11,5 %.
  • Mix: Kardiovaskulär +11 % auf 364,0 Mio. USD; Endoskopiegeräte +81 % auf 18,4 Mio. USD.
  • Margen: Bruttomarge 48,3 % (+60 Basispunkte); SG&A +19 %, F&E +20 % führten zu einem Rückgang der operativen Marge um 130 Basispunkte auf 12,3 %.
  • ٰä: Nettogewinn 32,6 Mio. USD (-8,8 %); verwässertes EPS 0,54 USD vs. 0,61 USD. 1H EPS 1,03 USD (-5,5 %).
  • Cashflow: Operativer Cashflow 1H 123,9 Mio. USD (+18 %); Investitionsausgaben 34,8 Mio. USD; Akquisitionen 122,6 Mio. USD.
  • Bilanz: Zahlungsmittel 341,8 Mio. USD (-9 % seit Jahresbeginn); langfristige Wandelanleihen 731,8 Mio. USD; Eigenkapital 1,49 Mrd. USD (+7,9 %). Verschuldungsklauseln bleiben eingehalten.
  • Akquisitionen: Im Mai Abschluss des Biolife-Deals über 126 Mio. USD (hämostatische Geräte); Integration von Cook (210 Mio. USD) und EGS (105 Mio. USD) läuft. Firmenwert jetzt 504,6 Mio. USD.
  • Steuern: Effektiver Steuersatz 24,9 % vs. 22,1 %, belastet die Erträge.

Insgesamt wurde das starke Umsatzwachstum und die Cashgenerierung durch höhere Betriebskosten, Akquisitionsausgaben und eine steigende Steuerquote ausgeglichen, was zu einem niedrigeren Jahresvergleichsergebnis führte.

Positive
  • Revenue growth of 13 % YoY and broad-based segment gains signal strong demand.
  • Gross margin expansion of 60 bp despite inflation indicates pricing/efficiency traction.
  • Operating cash flow up 18 % to $124 m enhances internal funding capacity.
  • Balance-sheet strength: $342 m cash and $697 m unused revolver provide liquidity for further R&D and M&A.
Negative
  • Diluted EPS fell 11 % YoY due to higher SG&A, R&D and tax rate.
  • Net margin compression: operating margin down 130 bp to 12.3 %.
  • Cash balance down 46 % vs prior-year quarter following heavy acquisition spend.
  • Interest expense remains elevated ($6.8 m in Q2) reflecting convertible-debt issuance.

Insights

TL;DR � Solid revenue beat, but cost inflation and taxes eroded EPS; outlook hinges on acquisition synergies.

Double-digit sales growth, particularly in peripheral and endoscopy lines, confirms healthy procedure volumes and early contribution from recent tuck-ins. Gross margin expanded slightly, yet SG&A and R&D rose faster (partly Biolife/Cook integration), trimming operating leverage. Interest and tax headwinds compounded, driving an 11 % EPS decline. Cash generation remains robust and liquidity ample, though cash pile fell following $123 m Biolife payment. Net leverage is manageable (<2× EBITDA est.) under covenant limits. Investors will focus on realizing cost synergies to restore earnings momentum and on potential dilution from 2029 converts if the stock trades above the ~$86.83 strike.

TL;DR � Biolife buy widens wound-closure portfolio and adds IP; integration risk appears contained.

Management paid ~4.2× projected 2025 sales for Biolife, securing patented StatSeal/WoundSeal technology with 12-year amortization life. Goodwill of $38 m signals expectation of cross-selling through Merit’s cardiovascular channel. Prior Cook and EGS assets are bedding in without material P&L disruption. Cumulative intangible amortization will step up (> $80 m in 2026), but cash tax impact is limited. No covenant stress post-deal: $697 m of revolver headroom and senior secured leverage at ~0×. Successful commercialization could lift organic growth above the current low-double-digit rate.

Merit Medical Systems (MMSI) � Sintesi 10-Q Q2 2025

  • Ricavi: 382,5 milioni di dollari, +13,1% su base annua; ricavi semestrali 737,8 milioni, +11,5%.
  • Composizione: Cardiovascolare +11% a 364,0 milioni; dispositivi per endoscopia +81% a 18,4 milioni.
  • Margini: Margine lordo al 48,3% (+60 punti base); SG&A +19%, R&S +20% hanno ridotto il margine operativo di 130 punti base al 12,3%.
  • Utile: Utile netto 32,6 milioni (-8,8%); EPS diluito 0,54$ contro 0,61$. EPS 1H 1,03$ (-5,5%).
  • Flusso di cassa: Flusso operativo 1H 123,9 milioni (+18%); investimenti fissi 34,8 milioni; acquisizioni 122,6 milioni.
  • Bilancio: Liquidità 341,8 milioni (-9% da inizio anno); obbligazioni convertibili a lungo termine 731,8 milioni; patrimonio netto 1,49 miliardi (+7,9%). I vincoli di leva finanziaria sono rispettati.
  • Acquisizioni: Concluso accordo Biolife da 126 milioni a maggio (dispositivi emostatici); integrazioni Cook (210 milioni) ed EGS (105 milioni) in corso. Avviamento ora 504,6 milioni.
  • 󾱲à: Aliquota effettiva 24,9% vs 22,1%, che ha pesato sugli utili.

In generale, la forte crescita dei ricavi e la generazione di cassa sono state compensate da costi operativi più elevati, spese per acquisizioni e un aumento dell’aliquota fiscale, portando a un utile inferiore rispetto all’anno precedente.

Merit Medical Systems (MMSI) � Resumen 10-Q Q2 2025

  • Ingresos: 382,5 millones de dólares, un aumento del 13,1% interanual; ingresos semestrales de 737,8 millones, +11,5%.
  • dzDzó: Cardiovascular +11% a 364,0 millones; dispositivos de endoscopía +81% a 18,4 millones.
  • áԱ: Margen bruto del 48,3% (+60 puntos base); SG&A +19%, I+D +20% redujeron el margen operativo en 130 puntos base al 12,3%.
  • Ganancias: Ingreso neto 32,6 millones (-8,8%); EPS diluido 0,54$ vs 0,61$. EPS primer semestre 1,03$ (-5,5%).
  • Flujo de caja: Flujo operativo primer semestre 123,9 millones (+18%); capex 34,8 millones; adquisiciones 122,6 millones.
  • Balance: Efectivo 341,8 millones (-9% en el año); notas convertibles a largo plazo 731,8 millones; patrimonio 1,49 mil millones (+7,9%). Los convenios de apalancamiento se mantienen cumplidos.
  • Adquisiciones: Cerrado acuerdo Biolife por 126 millones en mayo (dispositivos hemostáticos); integraciones previas de Cook (210 millones) y EGS (105 millones) en curso. Plusvalía ahora 504,6 millones.
  • Impuestos: Tasa efectiva 24,9% vs 22,1%, presionando las ganancias.

En general, el fuerte crecimiento de ingresos y generación de efectivo se vieron compensados por mayores costos operativos, gastos en adquisiciones y una tasa impositiva en aumento, lo que llevó a menores ganancias interanuales.

Merit Medical Systems (MMSI) � 2025� 2분기 10-Q 요약

  • 매출: 3� 8,250� 달러, 전년 동기 대� 13.1% 증가; 상반� 매출 7� 3,780� 달러, 11.5% 증가.
  • 구성: 심혈관 부� +11%� 3� 6,400� 달러; 내시� 기기 +81%� 1,840� 달러.
  • 마진: 총이익률 48.3% (+60bp); 판매관리비 19%, 연구개발� 20% 증가� 영업이익률은 130bp 하락� 12.3% 기록.
  • 수익: 순이� 3,260� 달러 (-8.8%); 희석 주당순이� 0.54달러, 전년 0.61달러 대� 하락. 상반� EPS 1.03달러 (-5.5%).
  • ˳금흐름: 상반� 영업현금흐름 1� 2,390� 달러 (+18%); 자본적지� 3,480� 달러; 인수합병 비용 1� 2,260� 달러.
  • 재무: 현금 3� 4,180� 달러 (-9% 연초 대�); 장기 전환사채 7� 3,180� 달러; 자본 14� 9,000� 달러 (+7.9%). 레버리지 조항 준� �.
  • 인수병: 5월에 1� 2,600� 달러 규모� Biolife 인수 완료(지혈기�); 이전 Cook(2� 1,000� 달러) � EGS(1� 500� 달러) 통합 진행 �. 영업� 현재 5� 460� 달러.
  • 세금: 유효세율 24.9% vs 22.1%, 수익� 부담으� 작용.

전반적으� 강한 매출 성장� 현금 창출은 운영 비용 증가, 인수 지�, 세율 상승으로 상쇄되어 전년 대� 수익� 감소했다.

Merit Medical Systems (MMSI) � Points clés du 10-Q T2 2025

  • Chiffre d'affaires : 382,5 M$, en hausse de 13,1 % en glissement annuel ; chiffre d'affaires semestriel de 737,8 M$, en hausse de 11,5 %.
  • Composition : Cardiovasculaire +11 % à 364,0 M$ ; dispositifs d’endoscopie +81 % à 18,4 M$.
  • Marges : Marge brute de 48,3 % (+60 points de base) ; SG&A +19 %, R&D +20 % ont fait baisser la marge opérationnelle de 130 points de base à 12,3 %.
  • Bénéfices : Résultat net 32,6 M$ (-8,8 %) ; BPA dilué 0,54$ contre 0,61$. BPA 1S 1,03$ (-5,5 %).
  • Flux de trésorerie : Flux de trésorerie opérationnel 1S 123,9 M$ (+18 %) ; capex 34,8 M$ ; acquisitions 122,6 M$.
  • Bilan : Trésorerie 341,8 M$ (-9 % depuis le début de l’année) ; obligations convertibles à long terme 731,8 M$ ; capitaux propres 1,49 Md$ (+7,9 %). Les clauses de levier restent respectées.
  • Acquisitions : Clôture de l’accord Biolife à 126 M$ en mai (dispositifs hémostatiques) ; intégrations en cours de Cook (210 M$) et EGS (105 M$). Goodwill désormais à 504,6 M$.
  • Fiscalité : Taux effectif de 24,9 % contre 22,1 %, ce qui pèse sur les bénéfices.

Dans l’ensemble, une forte croissance du chiffre d’affaires et une génération de trésorerie ont été compensées par des coûts opérationnels plus élevés, des dépenses d’acquisition et une hausse du taux d’imposition, entraînant une baisse des bénéfices en glissement annuel.

Merit Medical Systems (MMSI) � Q2 2025 10-Q Highlights

  • Umsatz: 382,5 Mio. USD, +13,1 % im Jahresvergleich; Halbjahresumsatz 737,8 Mio. USD, +11,5 %.
  • Mix: Kardiovaskulär +11 % auf 364,0 Mio. USD; Endoskopiegeräte +81 % auf 18,4 Mio. USD.
  • Margen: Bruttomarge 48,3 % (+60 Basispunkte); SG&A +19 %, F&E +20 % führten zu einem Rückgang der operativen Marge um 130 Basispunkte auf 12,3 %.
  • ٰä: Nettogewinn 32,6 Mio. USD (-8,8 %); verwässertes EPS 0,54 USD vs. 0,61 USD. 1H EPS 1,03 USD (-5,5 %).
  • Cashflow: Operativer Cashflow 1H 123,9 Mio. USD (+18 %); Investitionsausgaben 34,8 Mio. USD; Akquisitionen 122,6 Mio. USD.
  • Bilanz: Zahlungsmittel 341,8 Mio. USD (-9 % seit Jahresbeginn); langfristige Wandelanleihen 731,8 Mio. USD; Eigenkapital 1,49 Mrd. USD (+7,9 %). Verschuldungsklauseln bleiben eingehalten.
  • Akquisitionen: Im Mai Abschluss des Biolife-Deals über 126 Mio. USD (hämostatische Geräte); Integration von Cook (210 Mio. USD) und EGS (105 Mio. USD) läuft. Firmenwert jetzt 504,6 Mio. USD.
  • Steuern: Effektiver Steuersatz 24,9 % vs. 22,1 %, belastet die Erträge.

Insgesamt wurde das starke Umsatzwachstum und die Cashgenerierung durch höhere Betriebskosten, Akquisitionsausgaben und eine steigende Steuerquote ausgeglichen, was zu einem niedrigeren Jahresvergleichsergebnis führte.

FALSE000182810800018281082025-07-302025-07-300001828108us-gaap:CommonClassAMember2025-07-302025-07-300001828108us-gaap:WarrantMember2025-07-302025-07-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 30, 2025
AURORA INNOVATION, INC.
(Exact name of registrant as specified in its charter)

Delaware001-4021698-1562265
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(I.R.S. Employer
Identification Number)

1654 Smallman St, Pittsburgh, PA
15222
(Address of principal executive offices)(Zip Code)
(888) 583-9506
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading
Symbol(s)
Name of each
exchange on which registered
Class A common stock, par value $0.00001 per shareAURThe Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50AUROWThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02. Results of Operations and Financial Condition.

On July 30, 2025, Aurora Innovation, Inc. (the “Company”) announced its financial results for its quarter ended June 30, 2025. A copy of the Company’s Shareholder Letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.


Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT INDEX
Exhibit
No.
Description
99.1
Letter to Shareholders, dated July 30, 2025
104Cover Page Interactive Data File



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 30, 2025
AURORA INNOVATION, INC.
By:/s/ David Maday
Name:David Maday
Title:Chief Financial Officer


FAQ

How much did MMSI earn per share in Q2 2025?

Diluted EPS was $0.54, down from $0.61 a year earlier.

What drove Merit Medical Systems� revenue growth in Q2 2025?

Cardiovascular products added $364 m (+11 %) and endoscopy devices rose 81 % to $18 m, boosted by portfolio realignment and acquisitions.

How large is MMSI’s cash position after the Biolife acquisition?

Cash and cash equivalents were $341.8 million at 30 Jun 2025.

What is the status of Merit’s convertible notes?

The $747.5 m 3.0 % notes mature Feb 1 2029 with an initial conversion price of about $86.83 per share.

Did Merit meet its credit-facility covenants in Q2 2025?

Yes. The company reported compliance with leverage and interest-coverage ratios and has about $697 m borrowing capacity remaining.

What was the effective tax rate for Q2 2025?

The rate increased to 24.9 % from 22.1 % in the prior year.
Aurora Innovation Inc

NASDAQ:AUR

AUR Rankings

AUR Latest News

AUR Latest SEC Filings

AUR Stock Data

10.56B
1.00B
27.88%
69.49%
5.12%
Information Technology Services
Services-computer Integrated Systems Design
United States
PITTSBURGH